The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
With Biotech sector up and running with M&A on almost daily basis, having Avacta presenting at AACR twice and as we know now, it is the whole AVA platform, which Avacta will also discuss and the market will quickly understand the potential magnitude of the whole precision oncology market, as will the majors !
With the Conference starting Wednesday the 11th, one would assume that Tuesday the 10th will be pre conference day, with all the majors arriving and the same for the speakers and indeed Avacta with their first presentation due at midday Thursday, hence a license deal could very likely be announced tomorrow.
Post market prints could show size and price above current level.
In view of what will be a very upbeat presentation y Avacta in Boston, “ AVA6000 at pace “ and AVA3996 + AVA032 “ The data to be presented showcases the potential of our two therapeutic platforms to generate further high value clinical assets.”
One would expect further keen size buyers this afternoon, trusting a License deal to be announced next week prior to the presentation in Boston and ESMO in Madrid the following week.
French pharmaceutical giant Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics, according to people familiar with the matter. Mirati’s shares surged 45% — the most since 2017 — in New York trading.
Worth remembering that following the AACR conference in the US, we have the ESMO oncology conference in Madrid on the 20-24/10, with all the majors attending.
Excellent timing for Avacta having presented at the ACCR conference.
One of the majors presenting on Precision Oncology:
Friday:
Bayer - Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients’ Lives.
As mentioned before, this year’s ESMO conference will be dominated by precision oncology and M&A .